Eyepoint, Inc. · NASDAQ:EYPT
Eyepoint — EyePoint Pharmaceuticals — Investor Presentation (September 2023)
37 slides from Eyepoint's investor presentation, Sep 13, 2023
Slide 1: Investor Presentation September 2023
Investor Presentation September 2023 Exhibit 99.1
Slide 2: Forward-Looking Statements
Forward-Looking Statements Various statements made in this presentation are forward-looking, within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, and are inherently subject to risks, uncertainties and potentially inaccurate assumptions. All statements that address activit
Slide 3: Committed to developing therapeutics to improve the lives of patients with serious retinal disease
Committed to developing therapeutics to improve the lives of patients with serious retinal disease COMPANY OVERVIEW Pipeline represents multi billion-dollar opportunities EYP-1901 –bioerodible intravitreal (IVT) insert of patented vorolanib tyrosine kinase inhibitor (TKI) for retinal disease Topline
Slide 4: Pipeline Represents Multibillion Dollar Product Opportunities
Pipeline Represents Multibillion Dollar Product Opportunities Program Indication Discovery Pre-Clin Phase 1 Phase 2 Phase 3 Next Milestone EYP-1901 – (vorolanib in Durasert E™) wet AMD NPDR DME ack EYP-2301 - (Tie 2 Activation) DME wet AMD Complement Inhibition Programs GA Topline data in Q2 2024 To
Slide 5: Durasert Technology: Safe Sustained IVT Drug Delivery
DURASERT® TECHNOLOGY 5 | INVESTOR PRESENTATION Safe Sustained IVT Drug Delivery Used in four of six FDA approved intravitreal sustained delivery products Delivered by a single in-office IVT injection Continuous, stable release of drug with zero-order kinetics Durasert®: non-erodible YUTIQ® (Alimera)
Slide 6: EYP-1901 Delivers Vorolanib Using Durasert E
EYP-1901 Delivers VEGF Receptor Binding Vorolanib Using Durasert E™ Each insert ~1/5000 of vitreous volume A single IVT injection New MOA in potential treatment of VEGF mediated retinal diseases Positioned to be complementary to approved anti-VEGF therapies Sustained delivery of drug between ~8-9 mo
Slide 7: Vorolanib is a selective pan-VEGF receptor blocker
Vorolanib is a selective pan-VEGF receptor blocker WHY VOROLANIB? Composition of matter patent into 2037 Previous Phase 1 and Phase 2 clinical trials in wet AMD as an oral therapy showed compelling efficacy data with no ocular toxicity observed1,2 In-vivo studies demonstrate encouraging neuroprotect
Slide 8: Vorolanib Binds Receptors of All VEGF Growth Factors
Vorolanib Binds Receptors of All VEGF Growth Factors With Strong Affinity To VEGF Receptor 2 - A Receptor Associated With Blood Vessel Leakage Vorolanib inhibits pathways with key roles in angiogenesis and pathological vascular leakage Potent and selective pan–VEGF receptor inhibitor Does not inhibi
Slide 9: Vorolanib Demonstrated Retinal Neuroprotection In Validated Mouse Model
Vorolanib Demonstrated The Ability To Provide Retinal Neuroprotection In Validated Mouse Model 34% reduction in loss of contrast vision vs. control Mean Change in Contrast Vision at Day 16 from Baseline in Animals Treated with Vorolanib vs Vehicle Control Retinal thickness measured by vertical and h
Slide 10: EYP-1901 Phase 1 DAVIO Clinical Trial Results in Wet AMD
EYP-1901 PHASE 1 DAVIO CLINICAL TRIAL RESULTS IN WET AMD 10 | INVESTOR PRESENTATION
Slide 11: EYP-1901 Phase 1 DAVIO Clinical Trial Met All Objectives
EYP-1901 Phase 1 DAVIO Clinical Trial Met All Objectives FAVORABLE SAFETY PROFILE Stabilization of mean BCVA and OCT throughout 6 months was achieved 53% up to 6-months with no anti-VEGF supplemental injection 75% reduction in treatment burden at 6-months No ocular SAEs reported No drug-related syst
Slide 12: Favorable safety profile
Favorable safety profile No ocular serious adverse events (SAEs) No drug related systemic SAEs No drug related ocular or systemic toxicity No Durasert related toxicity or tolerance issues No dose limiting toxicity No ocular AEs of key interest observed No vitreous floaters, endophthalmitis, retinal
Slide 13: BCVA and CST Stable After Single Treatment Of EYP-1901
BCVA and CST Stable At 6 And 12 Months After Single Treatment Of EYP-1901 In The DAVIO Clinical Trial AVERAGE CHANGE IN BCVA FROM SCREENING VISIT AVERAGE CHANGE IN CST FROM SCREENING VISIT ALL (N=17) MONTHS ALL (N=17) MONTHS BCVA: best corrected visual acuity OCT: optical coherence tomography; CST:
Slide 14: Clinically Significant Reduction In Treatment Burden Of 75% At 6 Months
EYP-1901 Phase 1 DAVIO Clinical Trial Demonstrated Clinically Significant Reduction In Treatment Burden Of 75% At 6-Months 14 | INVESTOR PRESENTATION SOC Anti-VEGF Injections Before and After Treatment SOC (Anti-VEGF) + EYP-1901 Anti-VEGF No supplemental injection Missed visit Low dose (n=3) –70% Lo
Slide 15: Reduction In Treatment Burden Of 73% At 12 Months
EYP-1901 Phase 1 DAVIO Clinical Trial Maintained A Clinically Significant Reduction In Treatment Burden Of 73% At 12-Months 15 | INVESTOR PRESENTATION SOC Anti-VEGF Injections Before and After Treatment SOC (Anti-VEGF) + EYP-1901 Anti-VEGF No supplemental injection Missed visit Low dose (n=3) –66% L
Slide 16: 53% Of Patients Did Not Require Supplemental Anti-VEGF At 6 Months
EYP-1901 Phase 1 DAVIO Clinical Trial Demonstrated That 53% Of Patients Did Not Require Supplemental Anti-VEGF Treatment At 6-Months 35% 47% 41% 41% 71% 76% 35% 35% 53% 82% 82% 100% Median time to supplemental anti-VEGF: 6 months 16 | INVESTOR PRESENTATION
Slide 17: Phase 1 DAVIO Subgroup Analysis – Nine Subjects With No Excess Fluid
PHASE 1 DAVIO CLINICAL TRIAL IN WET AMD SUBGROUP ANALYSIS – NINE SUBJECTS WITH NO EXCESS FLUID AT SCREENING 17 | INVESTOR PRESENTATION EYP-1901
Slide 18: Subgroup With No Excess Fluid Showed Stable BCVA and CST At 6 Months
BCVA: best corrected visual acuity Mean change in BCVA from screening visit Mean change in CST from screening visit BCVA = -0.4 letters at 6 months CST on OCT = -1.0 microns at 6 months OCT: optical coherence tomography; CST: central subfield thickness DAVIO Subgroup of Eyes with No Excess Fluid At
Slide 19: Subgroup Showed Stable BCVA and CST Through 12 Months
DAVIO Subgroup With No Excess Fluid At Screening Showed Stable BCVA and CST Through 12-Months Mean change in BCVA from screening visit Mean change in CST from screening visit BCVA = -0.4 letters at 6 months +0.7 letters at 11 months -2.2 letters at 12 months CST on OCT = -1.0 microns at 6 months +0.
Slide 20: Subgroup Treatment Burden Reduction At 6 Months
DAVIO Subgroup With No Excess Fluid At Screening Showed A 92% Reduction In Treatment Burden At 6 Months SOC (Anti-VEGF) + EYP-1901 Low dose (n=2) -89% Low-mid dose (n=1) -100% Mid dose (n=5) -90% High dose (n=1) -100% SOC Anti-VEGF Injections Before and After Treatment Reduction in Average Monthly T
Slide 21: Subgroup Showed 89% Reduction In Treatment Burden At 12 Months
SOC (Anti-VEGF) + EYP-1901 SOC Anti-VEGF Injections Before and After Treatment SOC (Anti-VEGF) + EYP-1901 Anti-VEGF No supplemental injection Missed visit Low dose (n=2) -83% Low-mid dose (n=1) -100% Mid dose (n=5) -90% High dose (n=1) -83% Reduction in Average Monthly Treatment Burden at 12 Months
Slide 22: 67% Did Not Require Supplemental Anti-VEGF Injection
DAVIO Subgroup With No Excess fluid At Screening Demonstrated That 67% Did Not Require A Supplemental Anti-VEGF Injection At 6-Months Median time to supplemental anti-VEGF: 12 months 56% 67% 67% 67% 89% 56% 56% 67% 100% 100% 100% 100% DAVIO 12-month final data 22 | INVESTOR PRESENTATION
Slide 23: EYP-1901 Treat To Maintain In Wet AMD
EYP-1901 TREAT TO MAINTAIN IN WET AMD 23 | INVESTOR PRESENTATION
Slide 24: DAVIO Data Supports Advancing EYP-1901 As Maintenance Treatment For Wet AMD
DAVIO Clinical Trial Data Supports Advancing EYP-1901 As A Maintenance Treatment For Wet AMD About half of eyes in DAVIO could go up to 6 months on EYP-1901 alone Another ~30% received only a single supplemental anti-VEGF during 6-months About 15 % failed both SoC and EYP-1901 and required multiple
Slide 25: EYP-1901 Is Advancing As A Potential Maintenance Therapy In Wet AMD
EYP-1901 Is Advancing As A Potential Maintenance Therapy In Wet AMD Treat newly diagnosed patients with anti-VEGF of choice to reach desired “dry” outcome Maintain with EYP-1901on six-month intervals providing new MOA and sustained delivery Supplement with current anti-VEGF biologic, if needed 25 |
Slide 26: Wet AMD Phase 2 Clinical Trial - DAVIO 2
WET AMD PHASE 2 CLINICAL TRIAL - DAVIO 2 26 | INVESTOR PRESENTATION EYP-1901
Slide 27: DAVIO 2 Designed To Support Initiation Of Phase 3 Trials In 2024
The Phase 2 DAVIO 2 clinical trial for EYP-1901 in wet AMD was designed to support initiation of Phase 3 clinical trials in 2024 Phase 2 design includes DAVIO Phase 1 learnings and FDA interaction Type C meetings held with FDA CST below 350um at screening to eliminate poor responders to standard of
Slide 28: DAVIO 2 Is Randomized, Double-Masked, Aflibercept Controlled
EYP-1901 Phase 2 DAVIO 2 Clinical Trial Is Randomized, Double-Masked, Aflibercept Controlled With A Single EYP-1901 Treatment At Two Doses -D14 to -D7 D1 W4 W8 W12 W16 W24 W32 W36 to W56 W20 W28 EYP-1901 2mg low dose EYP-1901 3mg high dose Aflibercept q8W RANDOMIZATION REQUIRED AFLIBERCEPT INJECTION
Slide 29: DAVIO and DAVIO 2 Trials Patient Demographics
Phase 1 DAVIO and Phase 2 DAVIO 2 Trials Patient Demographics Phase 1 DAVIO Baseline Characteristics (N = 17)* Mean age, y (range) 77.4 (67-94) Female, % 76% Mean BCVA, ETDRS letters (range) 69 (38-85) Mean CST, μm (range) 299 (204-441) Phase 2 DAVIO 2 Baseline Characteristics (N = 160)** Mean age,
Slide 30: DAVIO 2 Masked Safety Summary As Of September 1, 2023
DAVIO 2 Masked Safety Summary As Of September 1, 2023 Data-Cut Off Key findings: No drug-related ocular SAEs No drug-related systemic SAEs 2 ocular SAEs: Retinal detachment in a study eye detected at week 1 (one week post initial aflibercept injection, prior to EYP-1901 injection) Retinal hemorrhage
Slide 31: Non-Proliferative Diabetic Retinopathy - Phase 2 Clinical Trial (PAVIA)
NON-PROLIFERATIVE DIABETIC RETINOPATHY - PHASE 2 CLINICAL TRIAL (PAVIA) 31 | INVESTOR PRESENTATION EYP-1901
Slide 32: Growing Global Diabetic Retinopathy Market
Diabetic Retinopathy Market Size Report. 2018-2020 (GrandViewResearch.com), Global Diabetic Retinopathy Market Size Report. Jan. 2022 (MarketDataForecast.com) Growing Global DR Market $12.27B Analysis includes North America, Europe, Asia Pacific, Latin America, Middle East, and Africa $12.27 billion
Slide 33: PAVIA Is Randomized Double-Masked, Single Injection With Sham Control
EYP-1901 Phase 2 PAVIA Clinical Trial Is Randomized Double-Masked, Single Injection With Sham Control As A 9-Month Treatment In NPDR EYP-1901 DOSING VISIT SCHEDULED SHAM INJECTION -D21 to –D5 D1 W4 W12 W24 W36 W48 EYP-1901 2mg low dose EYP-1901 3mg high dose Control Sham RANDOMIZATION EYP-1901 1⁰ EN
Slide 34: PAVIA Masked Safety Summary As Of September 1, 2023
PAVIA Masked Safety Summary As Of September 1, 2023 Data-Cut Off Key findings: No drug-related ocular SAEs No drug-related systemic SAEs 2 ocular SAEs, deemed not drug related by investigators: Hemorrhagic posterior vitreous detachment (PVD) in a study eye eight-week after dosing Macular edema leadi
Slide 35: Solid cash position and cash runway into 2025
Solid cash position and cash runway into 2025 while funding Phase 2 trials for EYP-1901 BALANCE SHEET Strong Balance Sheet $142.5M of cash and investments on June 30, 2023 All bank debt retired in May 2023 Cash runway into 2025 35 | INVESTOR PRESENTATION
Slide 36: Continued Execution And Well Funded Through Key EYP-1901 Milestones
Continued Execution And Well Funded Through Key EYP-1901 Milestones EYP-1901 Corporate ✓ DAVIO 1 trial complete 2Q 2022 ✓ DAVIO 2 trial initiated 3Q 2022 ✓ PAVIA trial initiated 3Q 2022 ✓ DAVIO 2 enrollment complete 1Q 2023 ✓ PAVIA enrollment complete 2Q 2023 DAVIO 2 topline data December 2023 DME T
Slide 37: Investor Presentation September 2023
Investor Presentation September 2023
EyePoint Pharmaceuticals — Investor Presentation (September 2023) on 6ix